NBP
NovaBridge Biosciences
Next earnings Aug 18, 2026 · consensus $-0.14 EPS
$2.14
▲ +8.08%$2.14▼ -11.57%
over 1Y
L $1.47H $6.56
Today+8.1%
1W+33.8%
1M+25.1%
3M-11.9%
YTD-49.9%
1Y-11.6%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Revenue grew 140.7% YoY; but unprofitable (net margin -7321.0%).
Revenue (FY2023) $632K · FY2023
NovaBridge Biosciences shows $632K in FY2023 revenue (+140.7% YoY), a -7321.0% net margin, and -20.0% ROE.
Supporting the case: revenue grew 140.7% YoY; conservative balance sheet (liabilities/equity 0.13x).
Is NBP a buy? The one-page verdict, explained →
The options angle
model · matches our verdictCovered call~60d expiry
- Long 100 shares @ ~2.14
- Short call 2 @ ~0.36 est
debit $178max +$22max −$177BE 1.78
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | -$1.55M | $632K | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | -$53.1M | -$72.0M | -$51.4M | -$94.3M |
| Net income | -$366M | -$371M | -$208M | -$22.2M | -$46.3M |
| Diluted EPS | -$2.09 | -$1.96 | -$1.09 | -$0.12 | -$0.21 |
| Net margin | — | 23923.5% | -32868.5% | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$41.1M
EV / EBITDA—
EV / Sales65.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-18.7%
FCF yield-8.3%
Quality & risk
ROIC (est.)-31.7%
Free cash flow-$20.6M
Total debt$4.22M
Net cash$206M
Altman Z-Score-2.45 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+41.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗4Period ending 2026-06-292026-06-30open ↗6-KPeriod ending 2026-06-292026-06-29open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-172026-06-22open ↗20-F/APeriod ending 2025-12-312026-06-16open ↗6-KPeriod ending 2026-06-162026-06-16open ↗6-KPeriod ending 2026-06-162026-06-16open ↗4Period ending 2026-05-302026-06-02open ↗4Period ending 2026-05-142026-05-18open ↗144Filing2026-05-14open ↗4Period ending 2026-04-242026-04-28open ↗3Period ending 2026-04-172026-04-22open ↗
Frequently asked
- Is NovaBridge Biosciences (NBP) a buy?
- NBP currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 140.7% YoY; but unprofitable (net margin -7321.0%).
- What is NovaBridge Biosciences's quality score?
- NBP scores 39.64424301958683/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001778016, latest 4 filed 2026-06-30) · EODHD · as of 7/5/2026, 7:48:08 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 5, 2026, 3:48 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.